Loading...
Header Logo
Keywords
Last Name
Institution

Connection

Peter Friedmann to Narcotics

This is a "connection" page, showing publications Peter Friedmann has written about Narcotics.

 
Connection Strength
 
 
 
1.622
 
  1. Stein MD, Friedmann PD. Optimizing opioid detoxification: rearranging deck chairs on the Titanic. J Addict Dis. 2007; 26(2):1-2.
    View in: PubMed
    Score: 0.364
  2. Warner EA, Friedmann PD. Laboratory testing for drug abuse. Arch Pediatr Adolesc Med. 2006 Aug; 160(8):854, author reply 854.
    View in: PubMed
    Score: 0.354
  3. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005 Nov; 20(11):1038-41.
    View in: PubMed
    Score: 0.336
  4. Rich JD, Boutwell AE, Shield DC, Key RG, McKenzie M, Clarke JG, Friedmann PD. Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005 Sep; 82(3):411-9.
    View in: PubMed
    Score: 0.326
  5. Taylor LE, Maynard MA, Friedmann PD, Macleod CJ, Rich JD, Flanigan TP, Sylvestre DL. Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy? J Addict Med. 2012 Sep; 6(3):179-85.
    View in: PubMed
    Score: 0.135
  6. Friedmann PD, Alexander JA, Yey Y, Nahra T, Soliman S, Pollack HA. Duration of nonmethadone outpatient treatment: results from a national survey. Subst Abus. 2006 Sep; 27(3):47-53.
    View in: PubMed
    Score: 0.089
  7. Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003 May; 98(5):673-84.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.